Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Activity
RulesProposed and final rules open for commentGrantsFederal funding opportunities and deadlinesPress releasesWhat agencies are announcing publiclyHearingsCongressional committee hearings and meetingsBillsLegislation, actions, amendments, and votes
Views
AgenciesEverything from a single federal agencyTopicsActivity grouped by policy areaOrganizationsCompanies, associations, and advocacy groupsCommitteesHouse, Senate, and joint committee activityLegislatorsMembers of Congress, service, bills, and votes
Pricing
LoginCreate account

Table of contents

DetailsRelated

NDI 1445 - Korglutide from Caregen Co. Ltd

FDA-2025-S-0023-0147Other
Document

Details

The document's own metadata, straight from the source system.

Title
NDI 1445 - Korglutide from Caregen Co. Ltd
Posted
Jul 9, 2026
Agency
Food and Drug Administration (FDA)
Topics
  • Food Safety & Nutrition
View on regulations.gov ↗
Related

Related documents

Other documents filed with this rulemaking.

View related documents
Supporting & Related Material
NDI 1443 - Heat-Killed (HK) Lactiplantibacillus plantarum beLP1 (beLP1) - Original NDI Notification
No comment periodJul 9, 2026
Supporting & Related Material
NDI 1445 - Korglutide - Original NDI Notification
No comment periodJul 9, 2026
Other
NDI 1441 - MaGOmegaTM from Solutex NA LLC
No comment periodJul 9, 2026
Other
NDI 1446 - VC-H1 (Plant-based collagen alternative) from RAWGA Inc.
No comment periodJul 9, 2026
Supporting & Related Material
NDI 1442 - Herbal Extract - ShaomaZhijing (T92) - Original NDI Notification
No comment periodJul 9, 2026
Other
NDI 1443 - Heat-Killed (HK) Lactiplantibacillus plantarum beLP1 (beLP1) from Bereum Co. Ltd
No comment periodJul 9, 2026
Supporting & Related Material
NDI 1448 - 7-Hydroxymitragynine - Original NDI Notification
No comment periodJul 9, 2026
Other
NDI 1442 - Herbal Extract - ShaomaZhijing (T92) from Tasly Pharmaceuticals Inc.
No comment periodJul 9, 2026

On this page

DetailsRelated
Government ContextGovernment Context

Track federal rulemaking documents, topics, and agencies — built on primary sources across the federal government.

ActivityRulesGrantsPress releases
ViewsAgenciesTopicsOrganizations
GuidesInstall Government ContextFive questions to ask your agentAll guides
CompanyAboutData sourcesPricing
LegalPrivacyTerms
© 2026 Government Context. Built on primary government sources.Not affiliated with any U.S. government agency.